Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    23402625 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Condition: Hepatocellular Carcinoma
Intervention: Drug: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.

Indicates status has not been verified in more than two years